Clinical Trials Browser

Phase 4 × INDUSTRY × Nivolumab × Clear all

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms

NCT04513522 2025-07-11

CheckMate 7C9

Phase 4 Completed

101 enrolled 12 charts

Kidney Neoplasms

NCT02869789 2023-06-15

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Phase 4 Completed

1,041 enrolled 18 charts

Lung Neoplasms

NCT02982954 2022-11-01

CHECKMATE 920

Phase 4 Completed

211 enrolled 21 charts

Carcinoma, Renal Cell

NCT02596035 2022-10-27

CheckMate 374

Phase 4 Completed

197 enrolled 16 charts

Carcinoma, Renal Cell